Epistem announces collaborative agreement with Global Health Investment Fund I, LLC.

Epistem Holdings Plc (Epistem), the personalised medicine and biotechnology company, announced that it has entered into a collaborative funding agreement with the Global Health Investment Fund I, LLC (GHIF) to support the roll-out of its Genedrive® molecular diagnostic platform as the company's tuberculosis assay enters pivotal field trials in key developing world locations.

Read the press release here.

Source: Epistem Holdings Plc

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By Epistem Holdings Plc

Published: July 24, 2014, 1:42 p.m.

Last updated: July 24, 2014, 1:45 p.m.

Tags: Diagnostics

Print Share